van Oosterom At

429 citations
20 papers · 371 · h-index 8

Impact in

Papers in

van Oosterom At

20 papers receiving 358 citations

Peers

van Oosterom At
Comparison fields: 5 of 63
  • Chemical Health and Safety 4
  • Oncology 148
  • Reproductive Medicine 38
  • Cancer Research 66
  • Pathology and Forensic Medicine 60
Replace Henry J. Durivage with:
Henry J. Durivage United States
C. Sessa Switzerland
Bertino United States
Jean Pierre Lotz France
M. Decatris United Kingdom
Yuichiro Kido Japan
Gustavo Ismael Belgium
H. Thomas United Kingdom
Vinodh R. Nannan Panday Netherlands
Daniel Patterson United Kingdom
van Oosterom At relative to Henry J. Durivage United States Henry J. Durivage's profile →
Citations per field
00.5×4.8×
Henry J. Durivage · 1×
Citations per year

Countries citing papers authored by van Oosterom At

Since Specialization
Citations

This map shows the geographic impact of van Oosterom At's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by van Oosterom At with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites van Oosterom At more than expected).

Fields of papers citing papers by van Oosterom At

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by van Oosterom At. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by van Oosterom At. The network helps show where van Oosterom At may publish in the future.

Co-authors

The 25 scholars most cited alongside van Oosterom At, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with van Oosterom At Line = papers co-authored together van Oosterom At links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1
cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II).
1987230
2
Immunohistochemical localization and chromatographic characterization of human chorionic gonadotropin in a bladder carcinoma.
198523
3
Response criteria phase II/phase III invasive bladder cancer.
198619
4
Pharmacokinetics of the cytostatic drugs used in the CMF-regimen.
198314
5
Induction and removal of cisplatin-DNA adducts in human cells in vivo and in vitro as measured by immunochemical techniques.
198813
6
Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment results of a study of the Gynaecological Cancer Cooperative Group of the EORTC and experience at The Netherlands Cancer Institute.
199210
7
The role of ifosfamide in the treatment of sarcomas.
19899
8
Determination of plasma concentrations of underivatized cyclophosphamide by capillary gas chromatography.
19828
9
Plasma levels during intravesical instillation of mitomycin-C.
19855
10
Vincristine, bleomycin, mitomycin C, cisplatin combination chemotherapy as additive treatment to radiotherapy in poor risk patients with squamous cell carcinoma of the uterine cervix.
19855
11
A multivariate analysis of prognostic factors in disseminated non-seminomatous testicular cancer.
19885
12
Combination chemotherapy preceding surgery in osteogenic sarcoma.
19855
13
A phase II study of Mitomycin C in refractory adcvanced breast cancer. A multi-centre pilot study.
19805
14
Intraperitoneal chemotherapy in ovarian carcinoma.
19875
15
Treatment of seminomas with chemotherapy.
19844
16
CA 125 and TPA as markers in ovarian carcinoma.
19854
17
Objective response criteria in phase II and phase III studies.
19884
18
Neoadjuvant/primary chemotherapy in cancer treatment: what advantage?
19991
19
Objective response criteria in prostate cancer.
19901
20
The human tumour colony-forming assay using fresh specimens.
19861

About van Oosterom At

van Oosterom At is a scholar working on Surgery, Pulmonary and Respiratory Medicine, Oncology, Molecular Biology and Reproductive Medicine, having authored 20 papers that have together received 371 indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (3 papers), Ovarian cancer diagnosis and treatment (3 papers), Testicular diseases and treatments (3 papers), Cancer Treatment and Pharmacology (2 papers), Chemotherapy-induced organ toxicity mitigation (2 papers), Urologic and reproductive health conditions (1 paper), Polyomavirus and related diseases (1 paper) and Bone Tumor Diagnosis and Treatments (1 paper). The work is most often cited by research in Chemical Health and Safety (4 citations), Oncology (148 citations), Reproductive Medicine (38 citations), Cancer Research (66 citations) and Pathology and Forensic Medicine (60 citations) van Oosterom At has collaborated with scholars based in Netherlands, Belgium and Japan. Frequent co-authors include Frits J. Berends, Lohman Ph, L. Dirix, J. Hermans, Philip Bedford, Hideyuki Akaza, R R Hall, Y Matsumura, Derek Raghavan and A Yagoda. Their work appears in journals such as PubMed.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact